• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

    5/16/25 8:35:00 AM ET
    $BLTE
    $COE
    $HCM
    $IH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Other Consumer Services
    Real Estate
    Get the next $BLTE alert in real time by email

    NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference ("dbVIC") held May 15th are now available for online viewing.

    VIEW PRESENTATIONS HERE

    The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section.

    May 15th Company Presentations

    Bavarian Nordic A/S ((Nasdaq Copenhagen: BAVA, OTC:BVNRY)
    Viomi Technology Co., Ltd. (NASDAQ:VIOT)
    Infineon Technologies AG ((Xetra: IFX, OTC:IFNNY)
    Clicks Group Ltd. ((JSE: CLS, OTC:CLCGY)
    First Pacific Company Ltd. ((HKEX: 142, OTC:FPAFY)
    HUTCHMED (China) Limited (AIM: HCM, NASDAQ:HCM, and HKEX:13)
    51Talk Online Education Group (NYSE:COE)
    Yiren Digital Ltd. (NYSE:YRD)
    ABB Ltd. ((SIX: ABBN, OTC:ABBNY)
    Belite Bio, Inc. (NASDAQ:BLTE)
    Epiroc AB ((Nasdaq Stockholm: EPIA, OTC:EPOAY)
    International Airlines Group ((LSE: IAG, MAD: IAG, OTC:ICAGY)
    BDO Unibank, Inc. ((PSE: BDO, OTC:BDOUY)
    iHuman Inc. (NYSE:IH)



    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    About Virtual Investor Conferences®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $BLTE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BLTE
    $COE
    $HCM
    $IH

    CompanyDatePrice TargetRatingAnalyst
    Belite Bio Inc
    $BLTE
    1/26/2026$195.00Buy
    BofA Securities
    Belite Bio Inc
    $BLTE
    1/6/2026$191.00Overweight
    Morgan Stanley
    Belite Bio Inc
    $BLTE
    12/2/2025$194.00Neutral → Outperform
    Mizuho
    Belite Bio Inc
    $BLTE
    11/24/2025$154.00Overweight
    Cantor Fitzgerald
    Belite Bio Inc
    $BLTE
    11/20/2025$105.00Neutral
    Mizuho
    HUTCHMED (China) Limited
    $HCM
    9/22/2025$13.75Equal-Weight → Underweight
    Morgan Stanley
    HUTCHMED (China) Limited
    $HCM
    5/13/2025Buy → Hold
    HSBC Securities
    Belite Bio Inc
    $BLTE
    12/14/2023$60.00Buy
    Maxim Group
    More analyst ratings

    $BLTE
    $COE
    $HCM
    $IH
    SEC Filings

    View All

    SEC Form 144 filed by Belite Bio Inc

    144 - BELITE BIO, INC (0001889109) (Subject)

    4/9/26 12:17:43 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    4/9/26 6:19:32 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by HUTCHMED (China) Limited

    6-K - HUTCHMED (China) Ltd (0001648257) (Filer)

    4/9/26 6:06:12 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $IH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Belite Bio with a new price target

    BofA Securities initiated coverage of Belite Bio with a rating of Buy and set a new price target of $195.00

    1/26/26 10:01:23 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Belite Bio with a new price target

    Morgan Stanley initiated coverage of Belite Bio with a rating of Overweight and set a new price target of $191.00

    1/6/26 8:54:10 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio upgraded by Mizuho with a new price target

    Mizuho upgraded Belite Bio from Neutral to Outperform and set a new price target of $194.00

    12/2/25 8:17:09 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $IH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chen Wan-Shan

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/13/26 4:15:08 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Lin Yu-Hsin

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/13/26 4:15:11 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chuang Hao-Yuan

    4 - BELITE BIO, INC (0001889109) (Issuer)

    4/13/26 4:15:07 PM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $IH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2026, taking place on April 17-22, 2026 in San Diego, California. Preclinical data for HMPL-A580, a first-in-class PI3K/PIKK-EGFR Antibody-Targeted Therapy Conjugate ("ATTC") will be presented. The payload of HMPL-A580 potently inhibited PI3K and PIKK family kinases, with IC50 ranging around 1 to 10 nM. Eurofins profiling across 418 kinases revealed the

    4/8/26 8:00:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

    SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ:BLTE), a clinical-stage development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its annual report on Form 20-F, containing audited consolidated financial statements for the year ended December 31, 2025, as filed with the Securities and Exchange Commission on March 31, 2026, is available through its website (https://www.belitebio.com). Shareholders may receive a hard copy of the annual report free of charge upon request. This press release is being issued pursuant to Nasdaq Listing Rule 5250(d)(1)(C). About Belite

    3/31/26 8:00:00 AM ET
    $BLTE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    BEIJING, March 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025.  Fourth Quarter 2025 HighlightsRevenues were RMB190.7 million (US$27.3 million), compared with RMB232.7 million in the same period last year.Gross profit was RMB127.5 million (US$18.2 million), compared with RMB156.4 million in the same period last year.Operating income was RMB9.0 million (US$1.3 mill

    3/31/26 6:06:00 AM ET
    $IH
    Other Consumer Services
    Real Estate

    $BLTE
    $COE
    $HCM
    $IH
    Leadership Updates

    Live Leadership Updates

    View All

    Viomi Technology Co., Ltd Appoints Malaysian Pop Star Shila Amzah as Brand Ambassador and Announces New AI Water Purifier Launch in Malaysia

    GUANGZHOU, China, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Viomi Technology Co., Ltd ("Viomi" or the "Company") (NASDAQ:VIOT), a leading technology company for home water solutions in China, today announced the appointment of renowned Malaysian singer Ms. Shila Amzah as its brand ambassador in Malaysia. Ms. Amzah will join Viomi for a product launch event in Malaysia on October 30, where the Company will unveil its new AI water purifier, INNO, designed to bring a smarter and safer drinking water lifestyle to local households. Mr. Xiaoping Chen, Founder and CEO of Viomi, commented: "We are thrilled to welcome Ms. Shila Amzah as our brand ambassador in Malaysia. Together, at our upcoming product

    10/20/25 9:00:28 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED" or the "Company") (Nasdaq/AIM:​HCM, HKEX:​13) today announces that Professor Tan Shao Weng, Daniel (Chen Shaowen) is appointed as an Independent Non-executive Director and a member of the Technical Committee of the Company with effect from October 15, 2025. Professor Tan, aged 47, has over 20 years of experience in oncology, with his main research interests focusing on thoracic, head and neck malignancies, and drug development. He is the head of the Division of Clinical Trials and Epidemiological Sciences and a senior consultant in the Division of Medical Oncology at the N

    10/14/25 4:30:00 AM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HUTCHMED Announces Appointment of Acting Chief Executive Officer

    HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave of absence from his duties as Chief Executive Officer due to health reasons. In light of this, the Board of Directors has appointed Mr Johnny Cheng, an Executive Director and Chief Financial Officer of the Company, as Acting Chief Executive Officer with immediate effect, in addition to his role as Chief Financial Officer. Dr Dan Eldar, Chairman and Non-executive Director, said, "The Board expresses its full support for Dr Su and wishes him a speedy recover

    8/24/25 8:20:00 PM ET
    $HCM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BLTE
    $COE
    $HCM
    $IH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

    SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

    12/17/24 4:07:04 PM ET
    $COE
    Other Consumer Services
    Real Estate

    Amendment: SEC Form SC 13G/A filed by Viomi Technology Co. Ltd

    SC 13G/A - Viomi Technology Co., Ltd (0001742770) (Subject)

    11/12/24 6:35:53 AM ET
    $VIOT
    Consumer Electronics/Appliances
    Consumer Discretionary

    Amendment: SEC Form SC 13D/A filed by 51Talk Online Education Group

    SC 13D/A - 51Talk Online Education Group (0001659494) (Subject)

    10/10/24 6:45:35 AM ET
    $COE
    Other Consumer Services
    Real Estate

    $BLTE
    $COE
    $HCM
    $IH
    Financials

    Live finance-specific insights

    View All

    iHuman Inc. Announces Fourth Quarter and Fiscal Year 2025 Unaudited Financial Results

    BEIJING, March 31, 2026 /PRNewswire/ -- iHuman Inc. (NYSE:IH) ("iHuman" or the "Company"), a leading provider of tech-powered, intellectual development products in China, today announced its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2025.  Fourth Quarter 2025 HighlightsRevenues were RMB190.7 million (US$27.3 million), compared with RMB232.7 million in the same period last year.Gross profit was RMB127.5 million (US$18.2 million), compared with RMB156.4 million in the same period last year.Operating income was RMB9.0 million (US$1.3 mill

    3/31/26 6:06:00 AM ET
    $IH
    Other Consumer Services
    Real Estate

    51Talk Online Education Group Announces the Results for the Fourth Quarter and Full Year 2025

    SINGAPORE, March 27, 2026 /PRNewswire/ -- 51Talk Online Education Group ("51Talk" or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, announced its unaudited results for the fourth quarter and full year ended December 31, 2025. Full Year 2025 Financial and Operating HighlightsGross billings[1] for 2025 were US$127.6 million, an 83.4% growth from US$69.6 million for 2024.Net revenues were US$95.6 million for 2025, an 88.6% increase from US$50.7 million for 2024.The number of active students with attended lesson consumption was approximately 170,300 in 2025, representing a 79.3% increase from approximately 95,000 for 2024.Operati

    3/27/26 7:35:00 AM ET
    $COE
    Other Consumer Services
    Real Estate

    51Talk Online Education Group to Report Fourth Quarter and Full Year 2025 Financial Results on Friday, March 27, 2026

    Earnings Call Scheduled for 8:00 a.m. ET on March 27, 2026SINGAPORE, March 25, 2026 /PRNewswire/ -- 51Talk Online Education Group ("51Talk", or the "Company") (NYSE American: COE), a global online education platform with core expertise in English education, today announced that it will report its unaudited financial results for the fourth quarter and full year ended December 31, 2025 on Friday, March 27, 2026, before the open of U.S. markets. The Company's management will host an earnings conference call at 8:00 a.m. U.S. Eastern Time on March 27, 2026 (8:00 p.m. Singapore/Beijing/Hong Kong time on March 27 , 2026).Dial-in details for the earnings conference call are as follows:United States

    3/25/26 7:20:00 AM ET
    $COE
    Other Consumer Services
    Real Estate